Evaluation of Everolimus Activity against Mycobacterium tuberculosis Using In Vitro Models of Infection
Antibiotics · 13.01.2023 · 12 (1) · 171
DOI: 10.3390/antibiotics12010171 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 13.01.2023. Verfasst von Delia Mercedes Bianco und 11 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie-Sezione di Microbiologia, Università Cattolica del Sacro …. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Catholic University of the Sacred Heart, MUR PNRR, RICERCA FINALIZZATA.
Abstract (Originalsprache)
Even though Everolimus has been investigated in a phase II randomized trial as a host-directed therapy (HDT) to treat tuberculosis (TB), an oncological patient treated with Everolimus for a neuroendocrine pancreatic neoplasia developed active TB twice and a non-tuberculous mycobacterial (NTM) infection in a year and a half time span. To investigate this interesting case, we isolated and genotypically characterized the Mycobacterium tuberculosis (Mtb) clinical strain from the patient and tested the effect of Everolimus on its viability in an axenic culture and in a peripheral blood mononuclear cell (PBMCs) infection model. To exclude strain-specific resistance, we tested the activity of Everolimus against Mtb strains of ancient and modern lineages. Furthermore, we investigated the Everolimus effect on ROS production and autophagy modulation during Mtb infection. Everolimus did not have a direct effect on mycobacteria viability and a negligible effect during Mtb infection in host cells, although it stimulated autophagy and ROS production. Despite being a biologically plausible HDT against TB, Everolimus does not exert a direct or indirect activity on Mtb. This case underlines the need for a careful approach to drug repurposing and implementation and the importance of pre-clinical experimental studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie-Sezione di Microbiologia, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
- Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario "A. Gemelli", IRCCS, 00168 Rome, Italy.
- Department of Neuroscience, Biophysics Section, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
- Renal Transplant Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.
- Dipartimento di Sicurezza e Bioetica, Sez. Malattie Infettive, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
- Mater Olbia Hospital, 07026 Olbia, Italy.
ORCID-Profile: Flavio De Maio, Giulia Santarelli, Giada Bianchetti, Giuseppe Maulucci, Maurizio Sanguinetti
Förderung
- Catholic University of the Sacred Heart
- MUR PNRR
- RICERCA FINALIZZATA
Zitieren
APA
Bianco, D. M., De Maio, F., Santarelli, G., Palucci, I., Salustri, A., Bianchetti, G., Maulucci, G., Citterio, F., Sanguinetti, M., Tamburrini, E., Sali, M., & Delogu, G. (2023). Evaluation of Everolimus Activity against Mycobacterium tuberculosis Using In Vitro Models of Infection. Antibiotics, 12(1), 171. https://doi.org/10.3390/antibiotics12010171
Vancouver
Bianco DM, De Maio F, Santarelli G, Palucci I, Salustri A, Bianchetti G, et al. Evaluation of Everolimus Activity against Mycobacterium tuberculosis Using In Vitro Models of Infection. Antibiotics. 2023;12(1):171. doi:10.3390/antibiotics12010171
BibTeX
@article{Bianco2023,
author = {Bianco, Delia Mercedes and De Maio, Flavio and Santarelli, Giulia and Palucci, Ivana and Salustri, Alessandro and Bianchetti, Giada and Maulucci, Giuseppe and Citterio, Franco and Sanguinetti, Maurizio and Tamburrini, Enrica and Sali, Michela and Delogu, Giovanni},
title = {Evaluation of Everolimus Activity against Mycobacterium tuberculosis Using In Vitro Models of Infection},
journal = {Antibiotics},
year = {2023},
volume = {12},
number = {1},
pages = {171},
doi = {10.3390/antibiotics12010171}
}
EUVIMED